Basic Toficalm Information

• INN (International Nonproprietary Name): Tofisopam
• Brand Names Available In Australia: Toficalm; Tofisign; Tofifresh; Tofiso; TOFIZIN; Nextril; Tofypeace; Emandaxin; Grandaxin
• ATC Code: N05BA23
• Forms & Dosages: Tablet 50mg, 100mg — Common packaging: blisters/boxes (10x10 tablets)
• Manufacturers In Australia: Not specified
• Registration Status In Australia: Not specified — practitioners typically consult the TGA ARTG and Special Access pathways before use
• OTC / Rx Classification: Prescription Only (Rx) in all regulated markets

Latest Research Highlights

Worried whether tofisopam really treats anxiety without the heavy sedation of diazepam?

Recent surveillance and small trials from 2022–2025 continue to show tofisopam has anxiolytic efficacy with a 2,3‑benzodiazepine profile that produces less overt sedation and less muscle relaxation than classic 1,4‑benzodiazepines such as diazepam and alprazolam.

International safety summaries list common adverse events as drowsiness, nausea and dizziness, with severe respiratory depression uncommon except when combined with other central nervous system depressants.

European post‑marketing data for Grandaxin and Indian pharmacovigilance reports for brands such as Toficalm/Tofiso indicate low rates of cognitive impairment but advise monitoring for dependence if treatment exceeds typical short courses of two to six weeks.

Australian peer‑reviewed reports are sparse, so clinicians in Australia generally rely on overseas cohorts and real‑world adverse event reports and check the TGA ARTG before clinical use.

Clinical Effectiveness In Australia

Can Australian prescribers expect the same results seen overseas?

Clinical use in Australia is primarily extrapolated from international data because tofisopam is not widely reported on the TGA public listing and local trials are limited.

Where it is used in Australia — for example via importation, private prescriptions or the Special Access Scheme — reported outcomes mirror international experience, with symptom reduction in generalised anxiety and adjustment disorders within one to two weeks and improved daytime functioning compared with sedating benzodiazepines.

Effectiveness in real practice is influenced by patient adherence, comorbid conditions and whether patients are receiving concurrent psychological therapies under Medicare mental health plans.

Clinicians should review any TGA adverse event reports if available and may rely on local GP or hospital audits to capture off‑label adjunctive use in depression or alcohol‑withdrawal contexts.

1. Registered vs Special Access: Registered = listed on TGA ARTG for ordinary supply; Special Access/Authorised Prescriber = pathways for unregistered medicines on a case‑by‑case basis.

Australian Access Routes: Importation, Private Prescription, Special Access Scheme (SAS) or Clinical Trial Supply.

Indications And Expanded Uses

What is tofisopam normally used for and when do clinicians consider it off‑label?

Internationally, labelled indications for tofisopam are anxiolytic treatment, with brand labels such as Grandaxin and Toficalm listing 50–100 mg two to three times daily for acute anxiety.

Off‑label uses reported globally and occasionally in Australia include adjunctive treatment for depressive symptoms that are resistant to first‑line therapies and as an adjunct in alcohol‑withdrawal care.

The lower sedative profile makes tofisopam an option when daytime functioning must be preserved, but in Australia these expanded uses should be treated as off‑label unless TGA registration or ARTG entry says otherwise and informed consent is documented.

Composition And Brand Landscape

Which brands and strengths will patients encounter when importing or ordering online?

Active ingredient is tofisopam, a 2,3‑benzodiazepine derivative distinct from classical 1,4‑benzodiazepines.

Common market brands include Toficalm, Tofisign, Tofifresh, Tofiso, TOFIZIN, Nextril, Tofypeace, Emandaxin and Grandaxin, typically as 50 mg and 100 mg tablets in blister packs commonly sold as 10x10.

Manufacturers named in supplied data include Torrent Pharmaceuticals, Egis and several Indian suppliers such as Apple Pharmaceuticals, Neuracle Lifesciences and Psychocare Health.

Retail pharmacy considerations: imported packs may differ in labelling and excipients, and pharmacists should verify authenticity, batch documentation and storage instructions when dispensing imported supplies.

Contraindications And Special Precautions

Who should not take tofisopam and what checks are essential before supply?

Absolute contraindications from the supplied data include known hypersensitivity to tofisopam, severe respiratory insufficiency, sleep apnoea syndrome, acute intoxication with alcohol or CNS depressants, and severe hepatic impairment.

Relative contraindications requiring close monitoring include existing psychiatric illness (risk of paradoxical reactions), mild to moderate hepatic or renal impairment, history of substance abuse, and frailty in the elderly.

Pregnancy and breastfeeding require caution in Australian practice because safety data are limited and treatment should be avoided unless the benefit clearly outweighs risk and counselling is documented.

Special focus is needed for Indigenous and remote populations who may have higher comorbidity burdens such as chronic respiratory disease and substance use, so extra screening and culturally safe informed consent are essential.

• Daily Living Restrictions: Advise patients not to drive or operate heavy machinery until they know how tofisopam affects them.
• Emergency Signs: Seek urgent care for severe drowsiness, breathing difficulties or marked confusion.

Dosage Guidelines

What dose do I start at and how long should I expect to stay on it?

Typical adult dosing from the supplied data is 50–100 mg two to three times daily for anxiety, with similar ranges used adjunctively in depressive symptoms or alcohol‑withdrawal contexts.

Treatment duration for anxiety or adjustment disorders is generally short, two to six weeks, with regular reassessment to reduce the risk of dependence.

Start low and titrate, especially in elderly patients and those with hepatic or renal impairment — consider an initial 50 mg once or twice daily in these groups.

Children are not generally recommended to use tofisopam because safety and efficacy are not established.

Interactions Overview

Which medicines or substances must I avoid while taking tofisopam?

The major interaction risk is additive central nervous system depression when combined with alcohol, opioids, sedative hypnotics, antipsychotics or other benzodiazepines, increasing sedation and the risk of respiratory depression.

Medications that affect hepatic metabolism may interact; review concomitant antidepressants, antiepileptics and strong cytochrome P450 modulators when considering tofisopam.

Food interactions are minimal, but alcohol is a clear contraindication while on tofisopam.

Australian e‑health records and PBS‑linked dispensing software often flag high‑risk combinations, and pharmacists should use these electronic tools and clinical pharmacology resources for specific alerts.

Cultural Perceptions And Patient Habits

How do Australian patients typically approach a medicine they haven't heard of?

Australian patients often favour pragmatic, cost‑sensitive solutions and rely on pharmacist advice and PBS subsidies where available.

For a medicine like tofisopam that is unfamiliar to many Australians, common consumer behaviours include searching online for brand names and prices, asking pharmacists for reassurance, and preferring brands with clear local distribution or known manufacturers.

Rural and remote patients face access barriers such as fewer local prescribers, pharmacy stock shortages and a higher reliance on mail‑order or telehealth scripts.

Telehealth e‑prescriptions and major pharmacy chains influence uptake, and pharmacists play a central role in counselling and checking imported supplies.

Cultural safety is important for Indigenous patients; clinicians should build trust, involve community health workers and tailor discussions about psychotropic medicines and adherence support.

Availability And Pricing Patterns

How easily can Australians get tofisopam and what will it cost?

Tofisopam is readily available in India and parts of Europe but not commonly marketed in Australia, which affects availability in major retail chains that usually stock TGA‑registered or PBS‑listed medicines.

When tofisopam is not ARTG‑listed, access in Australia typically occurs via private import, Special Access Scheme applications or clinical trial supplies.

Pricing disparities are common: Indian generics such as Toficalm tend to be cheaper in origin markets, while imported private prescriptions incur freight, customs and dispensing fees that increase the final cost to the patient.

Telehealth pharmacies may facilitate prescriptions and logistics, but they must comply with TGA regulations for importation and supply.

In our online pharmacy, toficalm is available without a prescription, with discreet delivery to Australia in 5‑14 days.

Comparable Medicines And Preferences

How does tofisopam compare with diazepam, alprazolam or buspirone?

Key comparators include diazepam and alprazolam (classic 1,4‑benzodiazepines), buspirone (a non‑benzodiazepine anxiolytic) and etizolam where available in some regions.

Pros for tofisopam are anxiolytic effectiveness with less sedation and motor impairment, which may support better daytime functioning compared with diazepam or alprazolam.

Cons include limited local registration in Australia, variable supply chains and less long‑term outcome data in Australian populations, plus a dependence risk if used for prolonged periods.

For acute severe panic or muscle spasm, classic benzodiazepines may still be preferred, while tofisopam or buspirone may suit chronic anxiety where sedation is a concern.

FAQ — Common Australian Patient Questions

Is Toficalm On The PBS?

Not typically; check current PBS listings and TGA ARTG for updates, and if not listed access is generally via private prescription or the Special Access Scheme.

Will It Make Me Sleepy?

It is less sedating than many benzodiazepines but drowsiness can occur, so avoid driving until you know how it affects you.

Can I Drink Alcohol While Taking It?

No; alcohol significantly increases the risk of severe drowsiness and respiratory depression when combined with tofisopam.

Is It Addictive?

There is a dependence risk with prolonged use; recommended treatment length is short (two to six weeks) with regular review.

• Storage: Store below 25°C, keep in original blister and protect from moisture.
• Missed Dose: Take when remembered unless close to the next dose; do not double up.
• Emergency Signs: Severe drowsiness, breathing difficulty, or marked confusion require urgent care.

Guidelines For Proper Use (Pharmacist Counselling & Prescriber Notes)

What should pharmacists and prescribers cover when supplying tofisopam?

Pharmacist counselling should confirm the indication and document informed consent for any off‑label use.

Review the full medication list for other central nervous system depressants and counsel on starting dose, likely time to effect, short duration (two to six weeks), and common side effects such as drowsiness, nausea and dizziness.

Advise patients to avoid alcohol and to delay driving or operating heavy machinery until they know their reaction to the medicine.

Prescribers should check the TGA ARTG and consider the Special Access Scheme for unregistered imports, and document the rationale when prescribing off‑label.

Monitoring should include baseline hepatic and renal assessment where relevant, sedation checks and signs of dependence, with a follow‑up arranged within one to two weeks of initiation.

• Pharmacist Counselling Checklist: indication, dose, duration, drug interactions, side effects, storage, when to seek medical help.
• Monitoring Schedule: baseline liver/renal tests if comorbidity; review at 1–2 weeks and reassess need for continuation at 4–6 weeks.

Delivery Across Australia